Connect with us

Hi, what are you looking for?

Friday, Mar 24, 2023
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


Reunion Neuroscience files lawsuit against Mindset Pharma for copying drug compound

The company is alleging that Mindset knowingly copied Reunion’s RE104 compound

Reunion Neuroscience files lawsuit against Mindset Pharma for copying drug compound
Photo via Reunion Neuroscience

This week, Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) filed a lawsuit alleging that  Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) copied Reunion’s compound.

Reunion announced the lawsuit on Tuesday in the United States District Court for the District of New Jersey, alleging that Mindset knowingly copied Reunion’s RE104 compound and misleadingly presented that exact composition to the Patent Office as Mindset’s invention while applying for U.S. Patent No. 11,591,353.

“Mindset disagrees with and denies the allegations set forth by Reunion. The Company plans to vigorously defend itself against this lawsuit,” Mindset said in a statement.

Mindset’s goal is to create next-generation pharmaceutical assets that take advantage of the breakthrough therapeutic potential of psychedelic drugs. Mindset is currently working on multiple innovative families of psychedelic compounds, as well as a cost-effective process for synthesizing psilocybin and its own proprietary compounds.

Furthermore, the company has partnered with the McQuade Center for Strategic Research and Development, a member of the Otsuka Pharmaceuticals family of companies, to co-develop its short-duration compounds, Mindset Families 2 & 4.

Read more: Reunion Neuroscience starts trading on the TSX

Read more: Field Trip facilitates beneficial psychedelic-assisted therapy for cancer patient

“Reunion is proud of its inventions to further its mission to improve the lives of patients and families who suffer from depression and other mental health disorders and intends to vigorously protect its intellectual property position to the fullest extent,” said the company in a statement.

Reunion’s primary asset, RE104, is a proprietary and original serotonergic psychedelic compound that is the only 4-OH-DiPT prodrug in clinical development. RE104 has the potential to rapidly relieve symptoms and provide long-lasting effectiveness as a potential treatment for postpartum depression.


Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


Cybin will pay Mindset an initial US$500K and 'development milestone payments' that could potentially total US$9.5M afterward

Industry update

Shares of GW skyrocketed nearly 50% after the companies revealed the largest acquisition in the cannabis sector to date


Canopy has a fair shot at winning its suit against GW, but the case might not have a widespread effect on US pot extractors,...


Sundial told investors it produced high-quality consistent cannabis while omitting how a customer was returning an alleged 554 kilograms of mouldy weed